Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?
Type 2 diabetes mellitus (T2DM) is a highly prevalent health condition in the aging
population. Older adults with T2DM have higher risks of cardiovascular disease, heart failure …
population. Older adults with T2DM have higher risks of cardiovascular disease, heart failure …
[HTML][HTML] Diuretics, SGLT2 inhibitors and falls in older heart failure patients: to prescribe or to deprescribe? A clinical review
EP van Poelgeest, ML Handoko, M Muller… - European geriatric …, 2023 - Springer
Purpose Both heart failure and its treatment with diuretics or SGLT2 inhibitors increase fall
risk in older adults. Therefore, decisions to continue or deprescribe diuretics or SGLT2 …
risk in older adults. Therefore, decisions to continue or deprescribe diuretics or SGLT2 …
[HTML][HTML] Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus …
Background Recent large clinical trials have demonstrated cardiovascular benefits of similar
overall magnitude for sodium–glucose cotransporter-2 inhibitor (SGLT-2i) and glucagon-like …
overall magnitude for sodium–glucose cotransporter-2 inhibitor (SGLT-2i) and glucagon-like …
[HTML][HTML] SGLT2 Inhibitors–The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review
S Seidu, V Alabraba, S Davies, P Newland-Jones… - Diabetes Therapy, 2024 - Springer
A substantial evidence base supports the use of sodium-glucose cotransporter-2 inhibitors
(SGLT2is) in the treatment of type 2 diabetes mellitus (T2DM). This class of medicines has …
(SGLT2is) in the treatment of type 2 diabetes mellitus (T2DM). This class of medicines has …
[HTML][HTML] Cardiovascular aging: from cellular and molecular changes to therapeutic interventions
A Vakka, JS Warren, K Drosatos - The journal of cardiovascular …, 2023 - ncbi.nlm.nih.gov
Progressive age-induced deterioration in the structure and function of the cardiovascular
system involves cardiac hypertrophy, diastolic dysfunction, myocardial fibrosis, arterial …
system involves cardiac hypertrophy, diastolic dysfunction, myocardial fibrosis, arterial …
[HTML][HTML] A Non-Coronary, Peripheral Arterial Atherosclerotic Disease (Carotid, Renal, Lower Limb) in Elderly Patients—A Review PART II—Pharmacological Approach …
M Piechocki, T Przewłocki, P Pieniążek… - Journal of Clinical …, 2024 - mdpi.com
Background: Aging is a key risk factor for atherosclerosis progression that is associated with
increased incidence of ischemic events in supplied organs, including stroke, coronary …
increased incidence of ischemic events in supplied organs, including stroke, coronary …
[HTML][HTML] Management of heart failure with preserved ejection fraction in elderly patients: effectiveness and safety
A Elkammash, SSC Tam, G Yogarajah, J You - Cureus, 2023 - ncbi.nlm.nih.gov
The proportion of the elderly population continues to increase due to the global increase in
longevity. Heart failure with preserved ejection fraction (HFpEF) is common in the elderly …
longevity. Heart failure with preserved ejection fraction (HFpEF) is common in the elderly …
Key results from observational studies and real‐world evidence of sodium‐glucose cotransporter‐2 inhibitor effectiveness and safety in reducing cardio‐renal risk
T Nyström - Diabetes, Obesity and Metabolism, 2024 - Wiley Online Library
Abstract Sodium‐glucose cotransporter 2 (SGLT2) inhibitors, originally designed to manage
blood sugar levels in individuals with type 2 diabetes (T2D), have emerged as a crucial …
blood sugar levels in individuals with type 2 diabetes (T2D), have emerged as a crucial …
[HTML][HTML] Incorporating prognosis into clinical decision-making for older adults with diabetes
WJ Deardorff, K Covinsky - Journal of General Internal Medicine, 2023 - Springer
Prognosis is important for guiding discussions between clinicians, patients, families, and
caregivers around many clinical decisions, including whether to continue screening for …
caregivers around many clinical decisions, including whether to continue screening for …
Investigating the place of sodium-glucose cotransporter-2 inhibitors and dual sodium-glucose cotransporter-1 and dual sodium-glucose cotransporter-2 inhibitors in …
T McKenzie, GM Hale, A Miner, J Colón Colón… - Heart Failure …, 2024 - Springer
Sodium-glucose cotransporter-2 inhibitors have been shown to have significant metabolic,
renal, and atherosclerotic cardiovascular disease benefits. Recent randomized controlled …
renal, and atherosclerotic cardiovascular disease benefits. Recent randomized controlled …